Vol. 4 No. 3 (2024)
Reimbursement Reviews

Upadacitinib (Rinvoq)

decorative image of the issue cover

Published March 14, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses upadacitinib (Rinvoq), 15 mg, 30 mg, and 45 mg once daily, extended-release tablets, oral.
  • Indication: For the treatment of adult patients with moderately to severely active Crohn disease who have demonstrated prior treatment failure, i.e., an inadequate response, loss of response, or intolerance to at least 1 conventional and/or biologic therapy